Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation

@inproceedings{Sloots2010EfficacyAS,
  title={Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation},
  author={Cornelius E. J. Sloots and An Rykx and Marina Cools and Ren{\'e} Kerstens and Martine De Pauw},
  booktitle={Digestive Diseases and Sciences},
  year={2010}
}
Opioid-induced constipation (OIC) has negative effects on quality of life (QOL). Prucalopride is a new, selective 5-HT4 agonist and enterokinetic with strong clinical data in chronic constipation. This study investigated the efficacy, safety, and tolerability of prucalopride in patients with noncancer pain and OIC. A phase II, double-blind, placebo-controlled study of 196 patients randomized to placebo (n = 66), prucalopride 2 mg (n = 66) or 4 mg (n = 64), for 4 weeks, was carried out. The… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Efficacy of 12-week treatment with prucalopride (Resolor) in patients with chronic constipation: combined results of three

  • M Camilleri, R Specht Gryp, R Kerstens, L. Vanderplassche
  • Dig Dis Sci
  • 2010

how should we interpret the recommendations? Clin Drug Investig

  • Johnson D. Treating chronic constipation
  • 2006;26:547–557. Dig Dis Sci
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…